Abstract
This paper reviews recent progress in the design and evaluation of MEK inhibitors as cancer therapeutics. Activation of the Ras / Raf / MEK / MAP kinase pathway has been implicated in uncontrolled cell proliferation and tumor growth. Mutated, oncogenic forms of Ras are found in 50% of colon, 90% of pancreatic and 30% of lung cancers. Recently, B-Raf mutations have been identified in more than 60% of malignant melanomas and from 40-70% of papillary thyroid cancers. MEK, a dual specificity kinase, is a key player in this pathway; it is downstream of both Ras and Raf and activates ERK1/2 through phosphorylation of key tyrosine and threonine residues. Representative examples of both ATP competitive and non-competitive inhibitors as well as natural product based inhibitors will be discussed.
Keywords: mek inhibitor, erk, arry-142886 (azd 6244), pd 0325901, ci-1040, cancer, map kinase, kinase inhibitor
Current Topics in Medicinal Chemistry
Title: Progress Towards Therapeutic Small Molecule MEK Inhibitors for Use in Cancer Therapy
Volume: 5 Issue: 2
Author(s): Eli M. Wallace, Joseph P. Lyssikatos, Tammie Yeh, James D. Winkler and Kevin Koch
Affiliation:
Keywords: mek inhibitor, erk, arry-142886 (azd 6244), pd 0325901, ci-1040, cancer, map kinase, kinase inhibitor
Abstract: This paper reviews recent progress in the design and evaluation of MEK inhibitors as cancer therapeutics. Activation of the Ras / Raf / MEK / MAP kinase pathway has been implicated in uncontrolled cell proliferation and tumor growth. Mutated, oncogenic forms of Ras are found in 50% of colon, 90% of pancreatic and 30% of lung cancers. Recently, B-Raf mutations have been identified in more than 60% of malignant melanomas and from 40-70% of papillary thyroid cancers. MEK, a dual specificity kinase, is a key player in this pathway; it is downstream of both Ras and Raf and activates ERK1/2 through phosphorylation of key tyrosine and threonine residues. Representative examples of both ATP competitive and non-competitive inhibitors as well as natural product based inhibitors will be discussed.
Export Options
About this article
Cite this article as:
Wallace M. Eli, Lyssikatos P. Joseph, Yeh Tammie, Winkler D. James and Koch Kevin, Progress Towards Therapeutic Small Molecule MEK Inhibitors for Use in Cancer Therapy, Current Topics in Medicinal Chemistry 2005; 5 (2) . https://dx.doi.org/10.2174/1568026053507723
DOI https://dx.doi.org/10.2174/1568026053507723 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Adaptogens—History and Future Perspectives
Adaptogens are pharmacologically active compounds or plant extracts that are associated with the ability to enhance the body’s stability against stress. The intake of adaptogens is associated not only with a better ability to adapt to stress and maintain or normalise metabolic functions but also with better mental and physical ...read more
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Challenges, Consequences and Possible Treatments of Anticancer Drug Discovery ll
The use of several compounds has been the subject of increasing interest in phytochemistry, biochemistry, and other fields of research at the chemistry-biology-ecosystems interface. In spite of the continued search for new anticancer drugs, cancer remains a leading cause of death. Cancer mortalities are expected to increase to 12.9 million, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
n-3 Polyunsaturated Fatty Acids as Signal Transduction Modulators and Therapeutical Agents in Cancer
Current Signal Transduction Therapy Stem Cell and Gene Therapeutic Strategies for the Treatment of Multiple Sclerosis
Current Molecular Medicine Graphical Abstracts:
Current Radiopharmaceuticals An Insight into Anticancer Bioactives from <i>Punica granatum</i> (Pomegranate)
Anti-Cancer Agents in Medicinal Chemistry Histone Acetylation in Neurodevelopment
Current Pharmaceutical Design Risk of Systemic Autoimmune Diseases with Antiarrhythmic Drugs in Arrhythmia Patients: A Retrospective Cohort Study
Endocrine, Metabolic & Immune Disorders - Drug Targets BRAF Inhibitor Therapy for Melanoma, Thyroid and Colorectal Cancers: Development of Resistance and Future Prospects
Current Cancer Drug Targets Quantitative Color Doppler Ultrasonography Measurement of Thyroid Blood Flow in Patients with Graves’ Disease
Current Medical Imaging Further Vitamin D Analogs
Current Vascular Pharmacology Roles of Histone Deacetylases in Angiogenic Cellular Processes
Current Angiogenesis (Discontinued) Association between Serum Vitamin D Level and Echocardiographic Abnormalities in Patients with Thalassemia Major
Cardiovascular & Hematological Disorders-Drug Targets PET Radiopharmaceuticals for Personalized Medicine
Current Drug Targets Strategy of Virtual Screening based Discovery of HSP90 C-terminal Inhibitors and Network Pharmacological Analysis
Current Pharmaceutical Biotechnology Potential Anti-cancer Drugs Commonly Used for Other Indications
Current Cancer Drug Targets The Effects of Sevoflurane or Remifentanil on the Stress Response to Surgical Stimulus
Current Pharmaceutical Design Progesterone Receptor Agonists and Antagonists as Anticancer Agents
Mini-Reviews in Medicinal Chemistry An Overview of Targeting Legumain for Inhibiting Cancers
Current Pharmaceutical Design Bladder Cancer: Update on Risk Factors, Molecular and Ultrastructural Patterns
Current Medicinal Chemistry The RNA Binding Protein HuR: a Promising Drug Target for Anticancer Therapy
Current Cancer Drug Targets Antineoplastic Activity of Monocrotaline Against Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry